Home›Genetics & Precision Medicine› Berrylyzer variant prioritization system shows promising performance in two prenatal genetic diagnosis cohorts
Berrylyzer variant prioritization system shows promising performance in two prenatal genetic diagnosis cohortsCan a new AI tool help find answers for parents during pregnancy?
medRxivPublished April 7, 2026Study authors: Meng, M.; Liu, L.; Du, Q.; Zhou, X.; Tian, Y.; Sun, K.; Li, N.; Zhang, P.; Lian, X.; Fan, N.; Zhu, N…DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider Berrylyzer's promising variant ranking performance in prenatal cohorts, but note the observational evidence requires prospective validation.
This observational cohort study evaluated Berrylyzer, a novel end-to-end variant prioritization system, in two independent real-world prenatal cohorts. The system was compared against three existing methods: Xrare, Exomiser, and PhenIX. The primary performance metric was the ranking of diagnostic variants, with Berrylyzer ranking 56.41% and 58.12% of variants first in the two cohorts. Its recall rates within the top 20 ranked variants were 94.02% and 97.42%, respectively.
Berrylyzer outperformed the comparator tools in recall rates within the top 20. For the two cohorts, its performance (94.02%/97.42%) was higher than Xrare (85.19%/87.08%), Exomiser (84.90%/85.98%), and PhenIX (82.05%/88.93%). The analysis also indicated robust performance across diverse disease categories, inheritance patterns, and analytical strategies, with comparable results using both free-text phenotype descriptions and standardized terminologies.
Safety and tolerability data were not reported. Key limitations include the observational design, which precludes causal inference, and the lack of reported sample size, p-values, confidence intervals, and absolute numbers for the performance metrics. The study did not report on clinical outcomes, only on variant ranking performance.
The findings suggest Berrylyzer may be a practical tool for integration into clinical prenatal diagnostic pipelines, potentially advancing precision medicine in this setting. However, clinicians should interpret these results cautiously as they represent technical performance in specific cohorts and require prospective validation to confirm clinical utility and generalizability.
Imagine waiting for a genetic answer during a high-risk pregnancy. The clock feels like it's ticking, and every day of uncertainty weighs heavily. A new study looked at whether an artificial intelligence tool called Berrylyzer could help cut through that wait by pinpointing the likely cause faster.
The research tested Berrylyzer using genetic data from two separate groups of real-world prenatal cases. The system successfully put the actual disease-causing genetic variant in the #1 spot roughly 56-58% of the time. Even more consistently, it included the right answer within its top 20 picks over 94% of the time in one group and 97% in the other. It performed better at this task than three other existing analysis tools it was compared against, and worked well across different types of genetic disorders and ways of describing a baby's features.
It's important to understand what this study shows and what it doesn't. This was an observational look back at how the tool sorted data, not a test of whether using it actually gets answers to families quicker or improves care. The researchers didn't report key details like the total number of cases studied or statistical measures of confidence for the performance numbers. The findings are promising for the tool's accuracy in these specific prenatal settings, but they're a first step. More research is needed to see how it performs in the hands of doctors and genetic counselors making real-time decisions.
What this means for you:
A new AI tool showed promise for finding prenatal genetic causes, but it's an early test.
Study Details
Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background: Artificial intelligence (AI)-driven variant prioritization has demonstrated substantial utility in expediting genetic diagnosis by ranking the most likely causative variants. While a variety of tools have been developed, few address the unique clinical and technical constraints in prenatal genetic diagnosis. Methods: We introduce Berrylyzer, a novel, end-to-end variant prioritization system applied to prenatal diagnosis.Inspired by clinician's reasoning process during variant interpretation, Berrylyzer applies a modular, stepwise scoring architecture that jointly integrates phenotypic and genomic evidence and delivers a ranked list of candidate variants, achieving high computational efficiency without compromising analytical rigor. Moreover, Berrylyzer natively supports both structured ontologies and free-text clinical narratives, enabling flexible integration into diverse clinical environments. Its performance was rigorously evaluated across two independent, real-world prenatal cohorts and benchmarked against three state-of-the-art methods: Xrare, Exomiser, and PhenIX. Results: Across the two datasets, Berrylyzer ranked 56.41% and 58.12% of diagnostic variants first, and achieved recall rates of 94.02% and 97.42% within top 20, respectively. Berrylyzer outperformed Xrare (85.19% and 87.08%), Exomiser (84.90% and 85.98%), and PhenIX (82.05% and 88.93%). Stratified analysis consistently demonstrated superior performance across diverse disease categories, inheritance patterns, and analytical strategies. Notably, Berrylyzer exhibited robustness regardless of phenotype forms, yielding comparable top 20 recall rates for free-text descriptions and standardized terminologies. Conclusion: Berrylyzer represents an accurate, interpretable, and computationally lightweight variant prioritization system for prenatal genetic diagnosis. The superior performance across heterogeneous diagnostic contexts enables it as a practical solution for seamless integration into clinical pipelines, thereby advancing precision medicine in prenatal settings.
